-
1
-
-
82755186811
-
Cytokine signaling: Birth of a pathway
-
J.J. O'Shea, M. Gadina, and Y. Kanno Cytokine signaling: birth of a pathway J Immunol 187 2011 5475 5478
-
(2011)
J Immunol
, vol.187
, pp. 5475-5478
-
-
O'Shea, J.J.1
Gadina, M.2
Kanno, Y.3
-
2
-
-
0042932806
-
Molecular phylogeny within type i cytokines and their cognate receptors
-
J.L. Boulay, J.J. O'Shea, and W.E. Paul Molecular phylogeny within type I cytokines and their cognate receptors Immunity 19 2003 159 163
-
(2003)
Immunity
, vol.19
, pp. 159-163
-
-
Boulay, J.L.1
O'Shea, J.J.2
Paul, W.E.3
-
3
-
-
0031919849
-
Jaks and STATs: Biological implications
-
W.J. Leonard, and J.J. O'Shea Jaks and STATs: biological implications Annu Rev Immunol 16 1998 293 322
-
(1998)
Annu Rev Immunol
, vol.16
, pp. 293-322
-
-
Leonard, W.J.1
O'Shea, J.J.2
-
4
-
-
0028234529
-
Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins
-
J.E. Darnell Jr., I.M. Kerr, and G.R. Stark Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins Science 264 1994 1415 1421
-
(1994)
Science
, vol.264
, pp. 1415-1421
-
-
Darnell, Jr.J.E.1
Kerr, I.M.2
Stark, G.R.3
-
5
-
-
0036731485
-
Stats: Transcriptional control and biological impact
-
D.E. Levy, and J.E. Darnell Jr. Stats: transcriptional control and biological impact Nat Rev Mol Cell Biol 3 2002 651 662
-
(2002)
Nat Rev Mol Cell Biol
, vol.3
, pp. 651-662
-
-
Levy, D.E.1
Darnell, Jr.J.E.2
-
6
-
-
0026632288
-
A protein tyrosine kinase in the interferon alpha/beta signaling pathway
-
L. Velazquez, M. Fellous, G.R. Stark, and S. Pellegrini A protein tyrosine kinase in the interferon alpha/beta signaling pathway Cell 70 1992 313 322
-
(1992)
Cell
, vol.70
, pp. 313-322
-
-
Velazquez, L.1
Fellous, M.2
Stark, G.R.3
Pellegrini, S.4
-
7
-
-
0027942119
-
Sharing of a common gamma chain, gamma c, by the IL-2, IL-4, and IL-7 receptors: Implications for X-linked severe combined immunodeficiency (XSCID)
-
W.J. Leonard, M. Noguchi, and S.M. Russell Sharing of a common gamma chain, gamma c, by the IL-2, IL-4, and IL-7 receptors: implications for X-linked severe combined immunodeficiency (XSCID) Adv Exp Med Biol 365 1994 225 232
-
(1994)
Adv Exp Med Biol
, vol.365
, pp. 225-232
-
-
Leonard, W.J.1
Noguchi, M.2
Russell, S.M.3
-
8
-
-
0028857954
-
Mutation of Jak3 in a patient with SCID: Essential role of Jak3 in lymphoid development
-
S.M. Russell, N. Tayebi, H. Nakajima, M.C. Riedy, J.L. Roberts, M.J. Aman, T.S. Migone, M. Noguchi, M.L. Markert, and R.H. Buckley Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development Science 270 1995 797 800
-
(1995)
Science
, vol.270
, pp. 797-800
-
-
Russell, S.M.1
Tayebi, N.2
Nakajima, H.3
Riedy, M.C.4
Roberts, J.L.5
Aman, M.J.6
Migone, T.S.7
Noguchi, M.8
Markert, M.L.9
Buckley, R.H.10
-
9
-
-
0029164841
-
Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)
-
P. Macchi, A. Villa, S. Giliani, M.G. Sacco, A. Frattini, F. Porta, A.G. Ugazio, J.A. Johnston, F. Candotti, and J.J. O'Shea Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID) Nature 377 1995 65 68
-
(1995)
Nature
, vol.377
, pp. 65-68
-
-
MacChi, P.1
Villa, A.2
Giliani, S.3
Sacco, M.G.4
Frattini, A.5
Porta, F.6
Ugazio, A.G.7
Johnston, J.A.8
Candotti, F.9
O'Shea, J.J.10
-
10
-
-
0030862399
-
Human severe combined immunodeficiency: Genetic, phenotypic, and functional diversity in one hundred eight infants
-
R.H. Buckley, R.I. Schiff, S.E. Schiff, M.L. Markert, L.W. Williams, T.O. Harville, J.L. Roberts, and J.M. Puck Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants J Pediatr 130 1997 378 387
-
(1997)
J Pediatr
, vol.130
, pp. 378-387
-
-
Buckley, R.H.1
Schiff, R.I.2
Schiff, S.E.3
Markert, M.L.4
Williams, L.W.5
Harville, T.O.6
Roberts, J.L.7
Puck, J.M.8
-
12
-
-
0033987746
-
Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
-
B.J. Druker, and N.B. Lydon Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia J Clin Invest 105 2000 3 7
-
(2000)
J Clin Invest
, vol.105
, pp. 3-7
-
-
Druker, B.J.1
Lydon, N.B.2
-
13
-
-
0033816156
-
Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors
-
E. Buchdunger, C.L. Cioffi, N. Law, D. Stover, S. Ohno-Jones, B.J. Druker, and N.B. Lydon Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors J Pharmacol Exp Ther 295 2000 139 145
-
(2000)
J Pharmacol Exp Ther
, vol.295
, pp. 139-145
-
-
Buchdunger, E.1
Cioffi, C.L.2
Law, N.3
Stover, D.4
Ohno-Jones, S.5
Druker, B.J.6
Lydon, N.B.7
-
14
-
-
0034665713
-
Structural mechanism for STI-571 inhibition of abelson tyrosine kinase
-
T. Schindler, W. Bornmann, P. Pellicena, W.T. Miller, B. Clarkson, and J. Kuriyan Structural mechanism for STI-571 inhibition of abelson tyrosine kinase Science 289 2000 1938 1942
-
(2000)
Science
, vol.289
, pp. 1938-1942
-
-
Schindler, T.1
Bornmann, W.2
Pellicena, P.3
Miller, W.T.4
Clarkson, B.5
Kuriyan, J.6
-
15
-
-
33845444046
-
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
-
B.J. Druker, F. Guilhot, S.G. O'Brien, I. Gathmann, H. Kantarjian, N. Gattermann, M.W. Deininger, R.T. Silver, J.M. Goldman, R.M. Stone, and F. Cervantes Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J Med 355 2006 2408 2417
-
(2006)
N Engl J Med
, vol.355
, pp. 2408-2417
-
-
Druker, B.J.1
Guilhot, F.2
O'Brien, S.G.3
Gathmann, I.4
Kantarjian, H.5
Gattermann, N.6
Deininger, M.W.7
Silver, R.T.8
Goldman, J.M.9
Stone, R.M.10
Cervantes, F.11
-
16
-
-
0037103424
-
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
-
G.D. Demetri, M. von Mehren, C.D. Blanke, A.D. Van den Abbeele, B. Eisenberg, P.J. Roberts, M.C. Heinrich, D.A. Tuveson, S. Singer, M. Janicek, and J.A. Fletcher Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 2002 472 480
-
(2002)
N Engl J Med
, vol.347
, pp. 472-480
-
-
Demetri, G.D.1
Von Mehren, M.2
Blanke, C.D.3
Van Den Abbeele, A.D.4
Eisenberg, B.5
Roberts, P.J.6
Heinrich, M.C.7
Tuveson, D.A.8
Singer, S.9
Janicek, M.10
Fletcher, J.A.11
-
17
-
-
0344987881
-
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome
-
J. Cools, D.J. DeAngelo, J. Gotlib, E.H. Stover, R.D. Legare, J. Cortes, J. Kutok, J. Clark, I. Galinsky, J.D. Griffin, and N.C. Cross A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome N Engl J Med 348 2003 1201 1214
-
(2003)
N Engl J Med
, vol.348
, pp. 1201-1214
-
-
Cools, J.1
Deangelo, D.J.2
Gotlib, J.3
Stover, E.H.4
Legare, R.D.5
Cortes, J.6
Kutok, J.7
Clark, J.8
Galinsky, I.9
Griffin, J.D.10
Cross, N.C.11
-
18
-
-
33947280081
-
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy
-
A. Hochhaus, H.M. Kantarjian, M. Baccarani, J.H. Lipton, J.F. Apperley, B.J. Druker, T. Facon, S.L. Goldberg, F. Cervantes, D. Niederwieser, and R.T. Silver Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy Blood 109 2007 2303 2309
-
(2007)
Blood
, vol.109
, pp. 2303-2309
-
-
Hochhaus, A.1
Kantarjian, H.M.2
Baccarani, M.3
Lipton, J.H.4
Apperley, J.F.5
Druker, B.J.6
Facon, T.7
Goldberg, S.L.8
Cervantes, F.9
Niederwieser, D.10
Silver, R.T.11
-
19
-
-
77953218598
-
Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: A 'head-to-head comparison'
-
G. Rosti, F. Castagnetti, G. Gugliotta, F. Palandri, G. Martinelli, and M. Baccarani Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison' Leuk Lymphoma 51 2010 583 591
-
(2010)
Leuk Lymphoma
, vol.51
, pp. 583-591
-
-
Rosti, G.1
Castagnetti, F.2
Gugliotta, G.3
Palandri, F.4
Martinelli, G.5
Baccarani, M.6
-
20
-
-
79955027327
-
Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)
-
K. Ghoreschi, M.I. Jesson, X. Li, J.L. Lee, S. Ghosh, J.W. Alsup, J.D. Warner, M. Tanaka, S.M. Steward-Tharp, M. Gadina, and C.J. Thomas Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550) J Immunol 186 2011 4234 4243
-
(2011)
J Immunol
, vol.186
, pp. 4234-4243
-
-
Ghoreschi, K.1
Jesson, M.I.2
Li, X.3
Lee, J.L.4
Ghosh, S.5
Alsup, J.W.6
Warner, J.D.7
Tanaka, M.8
Steward-Tharp, S.M.9
Gadina, M.10
Thomas, C.J.11
-
21
-
-
38049018155
-
A quantitative analysis of kinase inhibitor selectivity
-
M.W. Karaman, S. Herrgard, D.K. Treiber, P. Gallant, C.E. Atteridge, B.T. Campbell, K.W. Chan, P. Ciceri, M.I. Davis, P.T. Edeen, and R. Faraoni A quantitative analysis of kinase inhibitor selectivity Nat Biotechnol 26 2008 127 132
-
(2008)
Nat Biotechnol
, vol.26
, pp. 127-132
-
-
Karaman, M.W.1
Herrgard, S.2
Treiber, D.K.3
Gallant, P.4
Atteridge, C.E.5
Campbell, B.T.6
Chan, K.W.7
Ciceri, P.8
Davis, M.I.9
Edeen, P.T.10
Faraoni, R.11
-
22
-
-
0242332186
-
Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor
-
P.S. Changelian, M.E. Flanagan, D.J. Ball, C.R. Kent, K.S. Magnuson, W.H. Martin, B.J. Rizzuti, P.S. Sawyer, B.D. Perry, W.H. Brissette, and S.P. McCurdy Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor Science 302 2003 875 878
-
(2003)
Science
, vol.302
, pp. 875-878
-
-
Changelian, P.S.1
Flanagan, M.E.2
Ball, D.J.3
Kent, C.R.4
Magnuson, K.S.5
Martin, W.H.6
Rizzuti, B.J.7
Sawyer, P.S.8
Perry, B.D.9
Brissette, W.H.10
McCurdy, S.P.11
-
23
-
-
0742318929
-
The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models
-
E. Kudlacz, B. Perry, P. Sawyer, M. Conklyn, S. McCurdy, W. Brissette, Flanagan, and P. Changelian The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models Am J Transplant 4 2004 51 57
-
(2004)
Am J Transplant
, vol.4
, pp. 51-57
-
-
Kudlacz, E.1
Perry, B.2
Sawyer, P.3
Conklyn, M.4
McCurdy, S.5
Brissette, W.6
Flanagan7
Changelian, P.8
-
24
-
-
39749164515
-
Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis
-
A.J. Milici, E.M. Kudlacz, L. Audoly, S. Zwillich, and P. Changelian Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis Arthritis Res Ther 10 2008 R14
-
(2008)
Arthritis Res Ther
, vol.10
, pp. 14
-
-
Milici, A.J.1
Kudlacz, E.M.2
Audoly, L.3
Zwillich, S.4
Changelian, P.5
-
25
-
-
70349736206
-
Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis
-
M.G. Boy, C. Wang, B.E. Wilkinson, V.F. Chow, A.T. Clucas, J.G. Krueger, A.S. Gaweco, S.H. Zwillich, P.S. Changelian, and G. Chan Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis J Invest Dermatol 129 2009 2299 2302
-
(2009)
J Invest Dermatol
, vol.129
, pp. 2299-2302
-
-
Boy, M.G.1
Wang, C.2
Wilkinson, B.E.3
Chow, V.F.4
Clucas, A.T.5
Krueger, J.G.6
Gaweco, A.S.7
Zwillich, S.H.8
Changelian, P.S.9
Chan, G.10
-
26
-
-
84857761516
-
Phase IIb dose-ranging study of the oral jak inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
-
R. Fleischmann, M. Cutolo, M.C. Genovese, E.B. Lee, K.S. Kanik, S. Sadis, C.A. Connell, D. Gruben, S. Krishnaswami, G. Wallenstein, and B.E. Wilkinson Phase IIb dose-ranging study of the oral jak inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs Arthritis Rheum 64 2012 617 629
-
(2012)
Arthritis Rheum
, vol.64
, pp. 617-629
-
-
Fleischmann, R.1
Cutolo, M.2
Genovese, M.C.3
Lee, E.B.4
Kanik, K.S.5
Sadis, S.6
Connell, C.A.7
Gruben, D.8
Krishnaswami, S.9
Wallenstein, G.10
Wilkinson, B.E.11
-
27
-
-
84860388892
-
Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate
-
Y. Tanaka, M. Suzuki, H. Nakamura, S. Toyoizumi, and S.H. Zwillich Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate Arthritis Care Res 63 2011 1150 1158
-
(2011)
Arthritis Care Res
, vol.63
, pp. 1150-1158
-
-
Tanaka, Y.1
Suzuki, M.2
Nakamura, H.3
Toyoizumi, S.4
Zwillich, S.H.5
-
28
-
-
81255159058
-
Targeting JAK3 in kidney transplantation: Current status and future options
-
D. Wojciechowski, and F. Vincenti Targeting JAK3 in kidney transplantation: current status and future options Curr Opin Organ Transplant 16 2011 614 619
-
(2011)
Curr Opin Organ Transplant
, vol.16
, pp. 614-619
-
-
Wojciechowski, D.1
Vincenti, F.2
-
29
-
-
84859265115
-
Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, in the treatment of Rheumatoid arthritis: Open label, long-term extension studies up to 36 months
-
J. Wollenhaupt, J.C. Silverfield, E.B. Lee, S. Wood, K. Soma, L. Wang, H. Nakamura, Y. Komuro, C.I. Nduaka, and D. Gruben Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, in the treatment of Rheumatoid arthritis: open label, long-term extension studies up to 36 months Arthritis Rheum 63 10 Suppl 2011 161 162
-
(2011)
Arthritis Rheum
, vol.63
, Issue.10 SUPPL.
, pp. 161-162
-
-
Wollenhaupt, J.1
Silverfield, J.C.2
Lee, E.B.3
Wood, S.4
Soma, K.5
Wang, L.6
Nakamura, H.7
Komuro, Y.8
Nduaka, C.I.9
Gruben, D.10
-
30
-
-
80054118156
-
Tofacitinib (CP-690,550), an oral Jak inhibitor, in combination with traditional DMARDs: Phase 3 study in patients with active rheumatoid arthritis with inadequate response to DMARDs
-
J. Kremer, Z-G. Li, S. Hall, R. Fleischmann, M. Genovese, E. Martin-Mola, J. Isaacs, D. Gruben, G. Wallenstein, and S. Krishnaswami Tofacitinib (CP-690,550), an oral Jak inhibitor, in combination with traditional DMARDs: Phase 3 study in patients with active rheumatoid arthritis with inadequate response to DMARDs Ann Rheum Dis 70 Suppl 3 2011 170
-
(2011)
Ann Rheum Dis
, vol.70
, Issue.SUPPL. 3
, pp. 170
-
-
Kremer, J.1
Li, Z.-G.2
Hall, S.3
Fleischmann, R.4
Genovese, M.5
Martin-Mola, E.6
Isaacs, J.7
Gruben, D.8
Wallenstein, G.9
Krishnaswami, S.10
-
31
-
-
84866156845
-
A phase IIb dose-ranging study of the oral jak inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone
-
J.M. Kremer, S. Cohen, B.E. Wilkinson, C.A. Connell, J.L. French, J. Gomez-Reino, D. Gruben, K.S. Kanik, S. Krishnaswami, V. Pascual-Ramos, and G. Wallenstein A phase IIb dose-ranging study of the oral jak inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone Arthritis Rheum 64 2012 970 981
-
(2012)
Arthritis Rheum
, vol.64
, pp. 970-981
-
-
Kremer, J.M.1
Cohen, S.2
Wilkinson, B.E.3
Connell, C.A.4
French, J.L.5
Gomez-Reino, J.6
Gruben, D.7
Kanik, K.S.8
Krishnaswami, S.9
Pascual-Ramos, V.10
Wallenstein, G.11
-
32
-
-
67650093218
-
The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo
-
J.M. Kremer, B.J. Bloom, F.C. Breedveld, J.H. Coombs, M.P. Fletcher, D. Gruben, S. Krishnaswami, R. Burgos-Vargas, B. Wilkinson, C.A. Zerbini, and S.H. Zwillich The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo Arthritis Rheum 60 2009 1895 1905
-
(2009)
Arthritis Rheum
, vol.60
, pp. 1895-1905
-
-
Kremer, J.M.1
Bloom, B.J.2
Breedveld, F.C.3
Coombs, J.H.4
Fletcher, M.P.5
Gruben, D.6
Krishnaswami, S.7
Burgos-Vargas, R.8
Wilkinson, B.9
Zerbini, C.A.10
Zwillich, S.H.11
-
33
-
-
84857718168
-
Tofacitinib (CP-690,550), an oral janus kinase inhibitor, in combination with methotrexate reduced the progression of structural damage in patients with rheumatoid arthritis: A 24-month phase 3 study
-
D. van der Heijde, Y. Tanaka, R. Fleischmann, E.C. Keystone, J.M. Kremer, C.A.F. Zerbini, M. Cardiel, S.B. Cohen, P.T. Nash, and Y.W. Song Tofacitinib (CP-690,550), an oral janus kinase inhibitor, in combination with methotrexate reduced the progression of structural damage in patients with rheumatoid arthritis: a 24-month phase 3 study Arthritis Rheum 2011 2592
-
(2011)
Arthritis Rheum
, pp. 2592
-
-
Van Der Heijde, D.1
Tanaka, Y.2
Fleischmann, R.3
Keystone, E.C.4
Kremer, J.M.5
Zerbini, C.A.F.6
Cardiel, M.7
Cohen, S.B.8
Nash, P.T.9
Song, Y.W.10
-
34
-
-
84857885925
-
Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, in combination with methotrexate, in patients with active rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitors: A 6-month phase 3 study
-
B.R. Burmester Gerd-Reudiger, C. Charles-Schoeman, J. Wollenhaupt, B. Zerbini, C.A.F. Benda, D. Gruben, G. Wallenstein, S. Krishnaswami, S.H. Zwillich, and T. Koncz Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, in combination with methotrexate, in patients with active rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitors: a 6-month phase 3 study Arthritis Rheum 63 10 Suppl 2011 288
-
(2011)
Arthritis Rheum
, vol.63
, Issue.10 SUPPL.
, pp. 288
-
-
Burmester Gerd-Reudiger, B.R.1
Charles-Schoeman, C.2
Wollenhaupt, J.3
Zerbini, B.4
Benda, C.A.F.5
Gruben, D.6
Wallenstein, G.7
Krishnaswami, S.8
Zwillich, S.H.9
Koncz, T.10
-
35
-
-
39149103052
-
The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia
-
E. Kudlacz, M. Conklyn, C. Andresen, C. Whitney-Pickett, and P. Changelian The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia Eur J Pharmacol 582 2008 154 161
-
(2008)
Eur J Pharmacol
, vol.582
, pp. 154-161
-
-
Kudlacz, E.1
Conklyn, M.2
Andresen, C.3
Whitney-Pickett, C.4
Changelian, P.5
-
36
-
-
84857239335
-
The Jak inhibitor CP-690,550 (tofacitinib) inhibits tnf-induced chemokine expression in fibroblast-like synoviocytes: Autocrine role of type i interferon
-
S. Rosengren, M. Corr, G.S. Firestein, and D.L. Boyle The Jak inhibitor CP-690,550 (tofacitinib) inhibits tnf-induced chemokine expression in fibroblast-like synoviocytes: Autocrine role of type I interferon Ann Rheum Dis 71 2012 440 447
-
(2012)
Ann Rheum Dis
, vol.71
, pp. 440-447
-
-
Rosengren, S.1
Corr, M.2
Firestein, G.S.3
Boyle, D.L.4
-
37
-
-
84861827087
-
The jak inhibitor tofacitinib regulates synovitis through inhibition of interferon-gamma and interleukin-17 production by human CD4+ T cells
-
K. Maeshima, K. Yamaoka, S. Kubo, K. Nakano, S. Iwata, K. Saito, M. Ohishi, H. Miyahara, S. Tanaka, K. Ishii, and H. Yoshimatsu The jak inhibitor tofacitinib regulates synovitis through inhibition of interferon-gamma and interleukin-17 production by human CD4+ T cells Arthritis Rheum 64 2012 1790 1798
-
(2012)
Arthritis Rheum
, vol.64
, pp. 1790-1798
-
-
Maeshima, K.1
Yamaoka, K.2
Kubo, S.3
Nakano, K.4
Iwata, S.5
Saito, K.6
Ohishi, M.7
Miyahara, H.8
Tanaka, S.9
Ishii, K.10
Yoshimatsu, H.11
-
38
-
-
10044296324
-
The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing
-
M. Conklyn, C. Andresen, P. Changelian, and E. Kudlacz The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing J Leukoc Biol 76 2004 1248 1255
-
(2004)
J Leukoc Biol
, vol.76
, pp. 1248-1255
-
-
Conklyn, M.1
Andresen, C.2
Changelian, P.3
Kudlacz, E.4
-
39
-
-
28544446226
-
Effects of jak3 inhibition with CP-690,550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts
-
R. Paniagua, M.S. Si, M.G. Flores, G. Rousvoal, S. Zhang, O. Aalami, A. Campbell, P.S. Changelian, B.A. Reitz, and D.C. Borie Effects of jak3 inhibition with CP-690,550 on immune cell populations and their functions in nonhuman primate recipients of kidney allografts Transplantation 80 2005 1283 1292
-
(2005)
Transplantation
, vol.80
, pp. 1283-1292
-
-
Paniagua, R.1
Si, M.S.2
Flores, M.G.3
Rousvoal, G.4
Zhang, S.5
Aalami, O.6
Campbell, A.7
Changelian, P.S.8
Reitz, B.A.9
Borie, D.C.10
-
40
-
-
77954929352
-
The Jak inhibitor CP-690,550 preserves the function of CD4CD25FoxP3 regulatory T cells and inhibits effector T cells
-
V.D. Sewgobind, M.E. Quaedackers, L.J. van der Laan, R. Kraaijeveld, S.S. Korevaar, G. Chan, W. Weimar, and C.C. Baan The Jak inhibitor CP-690,550 preserves the function of CD4CD25FoxP3 regulatory T cells and inhibits effector T cells Am J Transplant 10 2010 1785 1795
-
(2010)
Am J Transplant
, vol.10
, pp. 1785-1795
-
-
Sewgobind, V.D.1
Quaedackers, M.E.2
Van Der Laan, L.J.3
Kraaijeveld, R.4
Korevaar, S.S.5
Chan, G.6
Weimar, W.7
Baan, C.C.8
-
41
-
-
62849108810
-
A randomized placebocontrolled study of INCB018424, a selective Janus kinase1& 2 (JAK1&2) inhibitor in rheumatoid arthritis
-
W. Williams, P. Scherle, J. Shi, R. Newton, E. McKeever, J. Fridman, T. Burn, K. Vaddi, R. Levy, and L. Moreland A randomized placebocontrolled study of INCB018424, a selective Janus kinase1& 2 (JAK1&2) inhibitor in rheumatoid arthritis Arthritis Rheum 58 2008 S431
-
(2008)
Arthritis Rheum
, vol.58
, pp. 431
-
-
Williams, W.1
Scherle, P.2
Shi, J.3
Newton, R.4
McKeever, E.5
Fridman, J.6
Burn, T.7
Vaddi, K.8
Levy, R.9
Moreland, L.10
-
42
-
-
77953208379
-
Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis
-
R.A. Mesa Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis IDrugs 13 2010 394 403
-
(2010)
IDrugs
, vol.13
, pp. 394-403
-
-
Mesa, R.A.1
-
43
-
-
80051986566
-
A randomized dose-ranging, placebo-controlled study of INCB028050, a selective JAK1 and JAK2 inhibitor in subjects with active rheumatoid arthritis
-
M.W. Greenwald, R. Fidelus-Gort, R. Levy, J. Liang, K. Vaddi, W.V. William, and R. Newton A randomized dose-ranging, placebo-controlled study of INCB028050, a selective JAK1 and JAK2 inhibitor in subjects with active rheumatoid arthritis Arthritis Rheum 62 Suppl 10 2010 2172
-
(2010)
Arthritis Rheum
, vol.62
, Issue.SUPPL. 10
, pp. 2172
-
-
Greenwald, M.W.1
Fidelus-Gort, R.2
Levy, R.3
Liang, J.4
Vaddi, K.5
William, W.V.6
Newton, R.7
-
44
-
-
84859270131
-
Dose ranging study of VX-509, an oral selective Jak3 inhibitor, as monotherapy in patients with active rheumatoid arthritis (RA)
-
G. Spencer-Green, F. Fan, B. Frankovic, X. Luo, T. Hoock, and N. Damjanov Dose ranging study of VX-509, an oral selective Jak3 inhibitor, as monotherapy in patients with active rheumatoid arthritis (RA) Arthritis Rheum 63 Suppl 10 2011 L3
-
(2011)
Arthritis Rheum
, vol.63
, Issue.SUPPL. 10
, pp. 3
-
-
Spencer-Green, G.1
Fan, F.2
Frankovic, B.3
Luo, X.4
Hoock, T.5
Damjanov, N.6
-
45
-
-
79954620949
-
A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis
-
K.L. Stump, L.D. Lu, P. Dobrzanski, C. Serdikoff, D.E. Gingrich, B.J. Dugan, T.S. Angeles, M.S. Albom, M.A. Ator, B.D. Dorsey, and B.A. Ruggeri A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis Arthritis Res Ther 13 2011 R68
-
(2011)
Arthritis Res Ther
, vol.13
, pp. 68
-
-
Stump, K.L.1
Lu, L.D.2
Dobrzanski, P.3
Serdikoff, C.4
Gingrich, D.E.5
Dugan, B.J.6
Angeles, T.S.7
Albom, M.S.8
Ator, M.A.9
Dorsey, B.D.10
Ruggeri, B.A.11
-
46
-
-
80053531618
-
Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2
-
L.D. Lu, K.L. Stump, N.H. Wallace, P. Dobrzanski, C. Serdikoff, D.E. Gingrich, B.J. Dugan, T.S. Angeles, M.S. Albom, J.L. Mason, and M.A. Ator Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2 J Immunol 187 2011 3840 3853
-
(2011)
J Immunol
, vol.187
, pp. 3840-3853
-
-
Lu, L.D.1
Stump, K.L.2
Wallace, N.H.3
Dobrzanski, P.4
Serdikoff, C.5
Gingrich, D.E.6
Dugan, B.J.7
Angeles, T.S.8
Albom, M.S.9
Mason, J.L.10
Ator, M.A.11
-
47
-
-
80051667225
-
JAK inhibitors in myeloproliferative neoplasms: Rationale, current data and perspective
-
A. Tefferi, and A. Pardanani JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective Blood Rev 25 2011 229 237
-
(2011)
Blood Rev
, vol.25
, pp. 229-237
-
-
Tefferi, A.1
Pardanani, A.2
-
48
-
-
80052492285
-
The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling
-
D. Ungureanu, J. Wu, T. Pekkala, Y. Niranjan, C. Young, O.N. Jensen, C.F. Xu, T.A. Neubert, R.C. Skoda, S.R. Hubbard, and O. Silvennoinen The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling Nat Struct Mol Biol 18 2011 971 976
-
(2011)
Nat Struct Mol Biol
, vol.18
, pp. 971-976
-
-
Ungureanu, D.1
Wu, J.2
Pekkala, T.3
Niranjan, Y.4
Young, C.5
Jensen, O.N.6
Xu, C.F.7
Neubert, T.A.8
Skoda, R.C.9
Hubbard, S.R.10
Silvennoinen, O.11
-
49
-
-
77956696835
-
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis
-
S. Verstovsek, H. Kantarjian, R.A. Mesa, A.D. Pardanani, J. Cortes-Franco, D.A. Thomas, Z. Estrov, J.S. Fridman, E.C. Bradley, S. Erickson-Viitanen, and K. Vaddi Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis N Engl J Med 363 2010 1117 1127
-
(2010)
N Engl J Med
, vol.363
, pp. 1117-1127
-
-
Verstovsek, S.1
Kantarjian, H.2
Mesa, R.A.3
Pardanani, A.D.4
Cortes-Franco, J.5
Thomas, D.A.6
Estrov, Z.7
Fridman, J.S.8
Bradley, E.C.9
Erickson-Viitanen, S.10
Vaddi, K.11
-
50
-
-
84857837774
-
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
-
C. Harrison, J.J. Kiladjian, H.K. Al-Ali, H. Gisslinger, R. Waltzman, V. Stalbovskaya, M. McQuitty, D.S. Hunter, R. Levy, L. Knoops, and F. Cervantes JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis N Engl J Med 366 2012 787 798
-
(2012)
N Engl J Med
, vol.366
, pp. 787-798
-
-
Harrison, C.1
Kiladjian, J.J.2
Al-Ali, H.K.3
Gisslinger, H.4
Waltzman, R.5
Stalbovskaya, V.6
McQuitty, M.7
Hunter, D.S.8
Levy, R.9
Knoops, L.10
Cervantes, F.11
-
51
-
-
84863393110
-
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
-
S. Verstovsek, R.A. Mesa, J. Gotlib, R.S. Levy, V. Gupta, J.F. DiPersio, J.V. Catalano, M. Deininger, C. Miller, R.T. Silver, and M. Talpaz A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis N Engl J Med 366 2012 799 807
-
(2012)
N Engl J Med
, vol.366
, pp. 799-807
-
-
Verstovsek, S.1
Mesa, R.A.2
Gotlib, J.3
Levy, R.S.4
Gupta, V.5
Dipersio, J.F.6
Catalano, J.V.7
Deininger, M.8
Miller, C.9
Silver, R.T.10
Talpaz, M.11
-
52
-
-
80054028202
-
Long-term outcome of treatment with ruxolitinib in myelofibrosis
-
A. Tefferi, M.R. Litzow, and A. Pardanani Long-term outcome of treatment with ruxolitinib in myelofibrosis N Engl J Med 365 2011 1455 1457
-
(2011)
N Engl J Med
, vol.365
, pp. 1455-1457
-
-
Tefferi, A.1
Litzow, M.R.2
Pardanani, A.3
-
54
-
-
80053385665
-
Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia
-
P.P. Zenatti, D. Ribeiro, W. Li, L. Zuurbier, M.C. Silva, M. Paganin, J. Tritapoe, J.A. Hixon, A.B. Silveira, B.A. Cardoso, and L.M. Sarmento Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia Nat Genet 43 2011 932 939
-
(2011)
Nat Genet
, vol.43
, pp. 932-939
-
-
Zenatti, P.P.1
Ribeiro, D.2
Li, W.3
Zuurbier, L.4
Silva, M.C.5
Paganin, M.6
Tritapoe, J.7
Hixon, J.A.8
Silveira, A.B.9
Cardoso, B.A.10
Sarmento, L.M.11
-
55
-
-
84862907593
-
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia
-
J. Zhang, L. Ding, L. Holmfeldt, G. Wu, S.L. Heatley, D. Payne-Turner, J. Easton, X. Chen, J. Wang, M. Rusch, and C. Lu The genetic basis of early T-cell precursor acute lymphoblastic leukaemia Nature 481 2012 157 163
-
(2012)
Nature
, vol.481
, pp. 157-163
-
-
Zhang, J.1
Ding, L.2
Holmfeldt, L.3
Wu, G.4
Heatley, S.L.5
Payne-Turner, D.6
Easton, J.7
Chen, X.8
Wang, J.9
Rusch, M.10
Lu, C.11
-
56
-
-
80051795878
-
Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia
-
M. Blink, T.D. Buitenkamp, M.M. van den Heuvel-Eibrink, A.A. Danen-van Oorschot, V. de Haas, D. Reinhardt, J.H. Klusmann, M. Zimmermann, M. Devidas, A.J. Carroll, and G. Basso Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia Leukemia 25 2011 1365 1368
-
(2011)
Leukemia
, vol.25
, pp. 1365-1368
-
-
Blink, M.1
Buitenkamp, T.D.2
Van Den Heuvel-Eibrink, M.M.3
Danen-Van Oorschot, A.A.4
De Haas, V.5
Reinhardt, D.6
Klusmann, J.H.7
Zimmermann, M.8
Devidas, M.9
Carroll, A.J.10
Basso, G.11
-
57
-
-
84861023172
-
Somatic STAT3 mutations in large granular lymphocytic leukemia
-
H.L. Koskela, S. Eldfors, P. Ellonen, A.J. van Adrichem, H. Kuusanmaki, E.I. Andersson, S. Lagstrom, M.J. Clemente, T. Olson, S.E. Jalkanen, and M.M. Majumder Somatic STAT3 mutations in large granular lymphocytic leukemia N Engl J Med 366 2012 1905 1913
-
(2012)
N Engl J Med
, vol.366
, pp. 1905-1913
-
-
Koskela, H.L.1
Eldfors, S.2
Ellonen, P.3
Van Adrichem, A.J.4
Kuusanmaki, H.5
Andersson, E.I.6
Lagstrom, S.7
Clemente, M.J.8
Olson, T.9
Jalkanen, S.E.10
Majumder, M.M.11
-
58
-
-
70949094349
-
The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors
-
M. Hedvat, D. Huszar, A. Herrmann, J.M. Gozgit, A. Schroeder, A. Sheehy, R. Buettner, D. Proia, C.M. Kowolik, H. Xin, and B. Armstrong The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors Cancer Cell 16 2009 487 497
-
(2009)
Cancer Cell
, vol.16
, pp. 487-497
-
-
Hedvat, M.1
Huszar, D.2
Herrmann, A.3
Gozgit, J.M.4
Schroeder, A.5
Sheehy, A.6
Buettner, R.7
Proia, D.8
Kowolik, C.M.9
Xin, H.10
Armstrong, B.11
-
59
-
-
80155171655
-
Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480
-
H. Xin, A. Herrmann, K. Reckamp, W. Zhang, S. Pal, M. Hedvat, C. Zhang, W. Liang, A. Scuto, S. Weng, and D. Morosini Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480 Cancer Res 71 2011 6601 6610
-
(2011)
Cancer Res
, vol.71
, pp. 6601-6610
-
-
Xin, H.1
Herrmann, A.2
Reckamp, K.3
Zhang, W.4
Pal, S.5
Hedvat, M.6
Zhang, C.7
Liang, W.8
Scuto, A.9
Weng, S.10
Morosini, D.11
-
60
-
-
80052158097
-
The mutational landscape of head and neck squamous cell carcinoma
-
N. Stransky, A.M. Egloff, A.D. Tward, A.D. Kostic, K. Cibulskis, A. Sivachenko, G.V. Kryukov, M.S. Lawrence, C. Sougnez, A. McKenna, and E. Shefler The mutational landscape of head and neck squamous cell carcinoma Science 333 2011 1157 1160
-
(2011)
Science
, vol.333
, pp. 1157-1160
-
-
Stransky, N.1
Egloff, A.M.2
Tward, A.D.3
Kostic, A.D.4
Cibulskis, K.5
Sivachenko, A.6
Kryukov, G.V.7
Lawrence, M.S.8
Sougnez, C.9
McKenna, A.10
Shefler, E.11
-
61
-
-
0029005549
-
Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I
-
T.S. Migone, J.X. Lin, A. Cereseto, J.C. Mulloy, J.J. O'Shea, G. Franchini, and W.J. Leonard Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I Science 269 1995 79 81
-
(1995)
Science
, vol.269
, pp. 79-81
-
-
Migone, T.S.1
Lin, J.X.2
Cereseto, A.3
Mulloy, J.C.4
O'Shea, J.J.5
Franchini, G.6
Leonard, W.J.7
-
62
-
-
0029069540
-
Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein
-
C.L. Yu, D.J. Meyer, G.S. Campbell, A.C. Larner, C. Carter-Su, J. Schwartz, and R. Jove Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein Science 269 1995 81 83
-
(1995)
Science
, vol.269
, pp. 81-83
-
-
Yu, C.L.1
Meyer, D.J.2
Campbell, G.S.3
Larner, A.C.4
Carter-Su, C.5
Schwartz, J.6
Jove, R.7
-
63
-
-
70350500225
-
STATs in cancer inflammation and immunity: A leading role for STAT3
-
H. Yu, D. Pardoll, and R. Jove STATs in cancer inflammation and immunity: a leading role for STAT3 Nat Rev Cancer 9 2009 798 809
-
(2009)
Nat Rev Cancer
, vol.9
, pp. 798-809
-
-
Yu, H.1
Pardoll, D.2
Jove, R.3
-
64
-
-
78649982367
-
STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors
-
H. Lee, J. Deng, M. Kujawski, C. Yang, Y. Liu, A. Herrmann, M. Kortylewski, D. Horne, G. Somlo, S. Forman, and R. Jove STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors Nat Med 16 2010 1421 1428
-
(2010)
Nat Med
, vol.16
, pp. 1421-1428
-
-
Lee, H.1
Deng, J.2
Kujawski, M.3
Yang, C.4
Liu, Y.5
Herrmann, A.6
Kortylewski, M.7
Horne, D.8
Somlo, G.9
Forman, S.10
Jove, R.11
-
65
-
-
77950833182
-
Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3
-
F. Yang, C. Brown, R. Buettner, M. Hedvat, R. Starr, A. Scuto, A. Schroeder, M. Jensen, and R. Jove Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3 Mol Cancer Ther 9 2010 953 962
-
(2010)
Mol Cancer Ther
, vol.9
, pp. 953-962
-
-
Yang, F.1
Brown, C.2
Buettner, R.3
Hedvat, M.4
Starr, R.5
Scuto, A.6
Schroeder, A.7
Jensen, M.8
Jove, R.9
|